Читать книгу Transfusion Medicine - Jeffrey McCullough - Страница 155

Three methods used for pathogen inactivation of FFP are also being used to treat platelets [118–121, 136–138]. Initial studies in healthy research subjects and studies in patients with thrombocytopenia indicate satisfactory platelet function for both the psoralen and riboflavin methods [138–140]. Successful clinical trials in Europe using psoralen‐treated platelets prepared by the buffy coat method [141] and in the United States using apheresis platelets [142, 143] have been reported, and those platelets are widely used in Europe [144]. Riboflavin‐treated platelets also appear to be clinically effective [145]. Follow‐up of large numbers of patients do not indicate any unexpected adverse consequences from use of the psoralen‐treated platelets [146].